Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04640168 · ClinicalTrials.gov registry record · Phase 3
Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
A Phase 3 study of COVID-19, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 1,010
- Enrollment target
- 20
- Study locations
NCT04640168 is a Phase 3 study of COVID-19 that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,010 participants, below the 55,209-participant average among 203 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT04640168, a Phase 3 study of COVID-19, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,010 participants
- Enrollment target
- 20
- Study locations
Study Summary
ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir. Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests, oropharyngeal (OP) swabs, plasma (Day 29), and serum for secondary research as well as clinical outcome data. However, if infection control or other restrictions limit the ability of the subject to return to the clinic, these visits may be conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. The primary objective is to evaluate the clinical efficacy of baricitinib + remdesivir versus dexamethasone + remdesivir as assessed by the mechanical ventilation free survival by Day 29.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dexamethasone
- DRUG Baricitinib
- DRUG Remdesivir
Study Locations (20)
California
- UCSF Fresno Center for Medical Education and Research - Clinical Research Center - Fresno
- University of California San Diego Health - Jacobs Medical Center - La Jolla
- University of California Los Angeles Medical Center - Westwood Clinic - Los Angeles
- University of California Irvine Medical Center - Infectious Disease - Orange
- VA Palo Alto Health Care System - Infectious Diseases - Palo Alto
- University of California Davis Medical Center - Internal Medicine - Infectious Disease - Sacramento
- Kaiser Permanente San Diego Medical Center - San Diego
- Naval Medical Center San Diego - Infectious Disease Clinic - San Diego
- University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine - San Francisco
- Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases - Stanford
- Cedars Sinai Medical Center - West Hollywood
Florida
- University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine - Gainesville
- University of Florida Health - Jacksonville - Department of Emergency Medicine - Jacksonville
- University of Miami Miller School of Medicine - Infectious Diseases - Miami
Colorado
- VA Eastern Colorado Health Care System - Aurora
- Denver Health Division of Hospital Medicine - Main Campus - Denver
Georgia
- Emory Vaccine Center - The Hope Clinic - Decatur
- Atlanta VA Medical Center - Infectious Diseases Clinic - Decatur
Alabama
- University of Alabama at Birmingham School of Medicine - Infectious Disease - Birmingham
District of Columbia
- Georgetown University Medical Center - Division of Infectious Diseases - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,010 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2021-06-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04640168
The ClinicalTrials.gov registry entry for NCT04640168 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,010 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,209-participant average among 203 other COVID-19 trials with a reported enrollment target (98% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT04640168 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT04640168 about?
NCT04640168 is a clinical study titled "Adaptive COVID-19 Treatment Trial 4 (ACTT-4)". ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir. Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subjects, it is prefe...
What is the current status of trial NCT04640168?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,010 participants. The study started on 2020-12-02. Estimated completion is 2021-06-18.
What conditions does trial NCT04640168 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04640168?
The interventions under investigation include: Placebo (OTHER), Dexamethasone (DRUG), Baricitinib (DRUG), Remdesivir (DRUG).
Who is sponsoring clinical trial NCT04640168?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04640168 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Immunogenicity of NVX-CoV2705
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.